The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia

por Laszlovszky, I., Dombi, Z.B., Balogh, Á., Barabássy, Á., Vass, G., Szatmári, B., Németh, G.
Publicado 2021

Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase

por Vass, G., Barabássy, Á., Laszlovszky, I., Sebe, B., Dombi, Z.B., Szatmári, B., Németh, G.
Publicado 2021

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials

por Dombi, Z.B., Acsai, K., Barabássy, Á., Sebe, B., Laszlovszky, I., Vass, G., Szatmári, B., Patel, M., Earley, W., Németh, G.
Publicado 2021